LOS ANGELES,
June 28, 2018 /PRNewswire/
-- CytRx Corporation (NASDAQ: CYTR),
a biopharmaceutical research and development company specializing
in oncology, today highlighted that aldoxorubicin licensee
NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed
the first patient in the Phase 1b
portion of a Phase 1b/2 clinical
trial for patients with triple negative breast cancer
(TNBC). This is the third trial conducted by NantCell which
will investigate aldoxorubicin combined with immunotherapy or
high-affinity natural killer (haNK) cell therapy in certain high
unmet need cancer indications. The first trial in
pancreatic cancer patients commenced in January 2018 and the second trial, for
patients with advanced squamous cell carcinoma, commenced in
February 2018.
Eric Curtis, CytRx's
President and Chief Operating Officer stated, "The initiation of
this third clinical trial speaks to NantCell's commitment to
investigating aldoxorubicin in combination with their proprietary
haNK cell therapy and working to identify effective treatment
alternatives for women challenged by TNBC, an aggressive, difficult
to treat type of breast cancer."
The trial titled "QUILT-3.067 NANT Triple Negative
Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated
Immunotherapy in Subjects With TNBC Who Have Progressed on or After
Standard-of-care Therapy,"
(NCT03387085) is a single-center,
open-label, Phase 1b/2 clinical trial
designed to evaluate the safety and efficacy of several combination
therapies, including combinations with aldoxorubicin, in subjects
with TNBC who have progressed on or after standard of care
therapies. This trial is expected to enroll approximately 79
patients. The primary endpoint for the Phase 1b portion of the trial is safety and the primary
endpoint for the Phase 2 portion of the trial is objective response
rate (ORR) by RECIST.
About Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a
particularly aggressive form of cancer whose cells do not have
estrogen, progesterone, or receptors of the HER2 protein. According
to the National Institutes of Health, it is estimated that between
10 and 20 percent of breast cancer patients are diagnosed with TNBC
and approximately 170,000 cases of TNBC have been reported annually
worldwide, with higher rates among women under 50 years old and
women of African American or Hispanic background. The disease may
also be associated with inherited mutations in the BRCA1
gene.
About CytRx Corporation
CytRx Corporation (Nasdaq: CYTR) is a biopharmaceutical company
with expertise in discovering and developing new therapeutics to
treat patients with cancer. CytRx's most advanced drug conjugate,
aldoxorubicin, is an improved version of the widely used
anti-cancer drug doxorubicin and has been out-licensed to NantCell,
Inc. CytRx's website is www.cytrx.com
About Centurion BioPharma Corporation
CytRx's wholly owned subsidiary, Centurion BioPharma
Corporation, is focused on advancing a portfolio of novel,
anti-cancer drug candidates that employ its LADR™ (Linker Activated
Drug Release) technology, a discovery engine designed to leverage
Centurion's expertise in albumin biology and linker technology for
the development of a new class of potential breakthrough
anti-cancer therapies. A critical element of the LADR™ platform is
its ability to bind anti-cancer molecules to albumin, the most
ubiquitous protein in human blood plasma, and then to release the
highly potent cytotoxic payload at the tumor site. This technology
allows for the delivery of higher doses of drug directly to the
tumor, while avoiding much of the off-target toxicity observed with
the parent molecules. The website is www.centurionbiopharma.com
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to obtain
regulatory approval for its products that use aldoxorubicin; the
ability of NantCell, Inc., to manufacture and commercialize
products or therapies that use aldoxorubicin; the amount, if any,
of future milestone and royalty payments that we may receive from
NantCell, Inc.; Centurion BioPharma Corporation's ability to
develop new ultra-high potency drug candidates based on its LADR™
technology platform; our ability to attract potential licensees;
and other risks and uncertainties described in the most recent
annual and quarterly reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date of
CytRx's most recent annual report. All forward-looking statements
are based upon information available to CytRx on the date the
statements are first published. CytRx undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212)
600-1902
cytrx@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-highlights-aldoxorubicin-included-in-new-nantcell-inc-triple-negative-breast-cancer-clinical-trial-300673826.html
SOURCE CytRx Corporation